viscer
leishmaniasi
vl
caus
leishmania
infantum
syn
leishmania
chagasi
sever
fatal
form
leishmaniasi
left
untreat
symptom
begin
dog
extrem
suscept
infect
consid
import
domest
reservoir
parasit
thu
canin
viscer
leishmaniasi
cvl
repres
seriou
public
health
problem
human
veterinari
medicin
variou
area
globe
includ
region
america
mediterranean
basin
asia
europ
often
preval
infect
dog
endem
area
high
anim
develop
variabl
clinic
sign
infect
also
subclin
case
addit
subclin
infect
dog
symptomat
anim
import
reservoir
infect
sandfli
current
control
strategi
interrupt
transmiss
includ
systemat
treatment
human
case
vector
control
elimin
seroposit
dog
recent
increas
drug
resist
toxic
chemotherapi
difficulti
epidemiolog
control
document
therefor
develop
vaccin
cvl
control
canin
diseas
reduc
incid
human
vl
fundament
urgent
signific
effort
made
sever
group
develop
vaccin
cvl
lemesr
et
al
use
secondgener
vaccin
contain
l
infantum
secretedexcret
protein
formul
muramyldipeptid
mdp
obtain
protect
beagl
efficaci
protect
endem
area
franc
year
followup
contrast
recombin
vaccin
like
multicompon
fusion
protein
associ
differ
adjuv
mplse
adjuprim
show
signific
immunogen
result
dog
challeng
l
infantum
fail
prevent
natur
l
infantum
infect
progress
diseas
open
kennel
trial
addit
vaccin
compos
glycoprot
complex
ligand
associ
saponin
dodg
show
vaccin
efficaci
dog
field
assay
endem
area
brazil
anoth
vaccin
licens
brazil
compos
recombin
protein
formul
saponin
calier
also
test
kennel
assay
phase
ii
present
high
level
specif
antibodi
posit
parasit
bone
marrow
four
seven
vaccin
dog
month
post
experiment
challeng
l
infantum
consid
wide
spectrum
antigen
cost
safeti
vaccin
compos
crude
antigen
also
repres
excel
tool
immunoprophylaxi
control
cvl
endem
area
research
group
develop
vaccin
cvl
compos
l
braziliensi
antigen
plu
saponin
adjuv
lbsap
vaccin
previou
studi
lbsap
vaccin
shown
safe
use
ulcer
lesion
observ
inocul
site
also
demonstr
vaccin
immunogen
includ
increas
immunoglobulin
isotyp
higher
level
lymphocyt
particularli
circul
lymphocyt
intens
cell
prolifer
product
vitro
stimul
higher
level
leishmaniaspecif
lymphocyt
three
dose
dog
consid
promis
result
lbsap
vaccin
aim
studi
evalu
immunogen
perform
parasitolog
analysi
challeng
intraderm
inoculum
l
infantum
plu
salivari
gland
extract
sge
lutzomyia
longipalpi
day
later
also
evalu
cellular
immun
respons
employ
realtim
pcr
determin
cytokin
profil
parasit
burden
spleen
studi
use
lbsap
vaccin
previous
describ
giunchetti
et
al
regist
instituto
nacion
da
propriedad
industri
patent
pi
rio
de
janeiro
rj
brazil
compos
l
braziliensi
crude
antigen
saponin
adjuv
twenti
male
femal
mongrel
dog
born
rear
kennel
anim
scienc
center
universidad
feder
de
ouro
preto
ouro
preto
mina
gerai
brazil
dog
treat
month
anthelmint
vaccin
rabi
tecpar
curitibapr
brazil
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
htlp
pfizer
anim
health
new
york
ny
usa
absenc
specif
antileishmania
antibodi
confirm
indirect
fluoresc
immunoassay
enzymelink
immunosorb
assay
elisa
test
experiment
dog
sort
four
experiment
group
follow
control
group
c
n
receiv
ml
steril
salin
ii
lb
group
n
receiv
l
braziliensi
promastigot
protein
ml
steril
salin
iii
sap
group
n
receiv
mg
saponin
sigma
chemic
co
st
loui
mo
usa
ml
steril
salin
iv
lbsap
group
n
receiv
l
braziliensi
promastigot
protein
mg
saponin
ml
steril
salin
case
anim
receiv
three
subcutan
inject
right
flank
interv
week
three
half
month
day
last
vaccin
dose
dog
challeng
intraderm
rout
right
ear
latelogphas
l
infantum
promastigot
plu
sge
obtain
two
acini
salivari
gland
lutzomyia
longipalpi
evalu
humor
cellular
immun
respons
perform
challeng
tbc
ie
day
experiment
challeng
day
challeng
dac
dog
euthan
dac
tissu
collect
evalu
cytokin
profil
parasit
load
peripher
blood
ml
collect
jugular
vein
dog
transfer
tube
contain
suffici
edta
produc
final
concentr
mgml
absolut
count
lymphocyt
sampl
obtain
use
vet
auto
hematolog
analyz
mindray
china
blood
sampl
store
room
temperatur
h
prior
process
humor
immun
respons
evalu
use
solubl
lysat
l
infantum
antigen
slca
accord
convent
elisa
previous
describ
rei
et
al
giunchetti
et
al
unlabel
canin
monoclon
antibodi
mab
clone
clone
clone
antimhcii
clone
purchas
serotec
usa
use
indirect
immunofluoresc
procedur
pool
normal
rat
serum
dilut
employ
isotyp
control
fluorescein
isothiocyan
fitc
label
igg
sheep
antirat
polyclon
antibodi
use
secondari
antibodi
fitclabel
mous
clone
iobla
mous
clone
mab
use
direct
immunofluoresc
assay
briefli
micropl
assay
immunophenotyp
canin
whole
blood
leukocyt
fresh
blood
sampl
peripher
blood
mononuclear
cell
pbmc
obtain
vitro
stimul
carri
accord
method
previous
describ
giunchetti
et
al
rei
et
al
result
express
percentag
posit
cell
within
select
gate
cell
surfac
marker
present
bimod
distribut
semiquantit
analys
carri
cell
surfac
marker
mhcii
result
express
mean
fluoresc
channel
log
scale
describ
giunchetti
et
al
vitro
evalu
pbmc
isol
ml
heparinis
blood
layer
onto
ml
densiti
gradient
sigma
chemic
co
centrifug
min
room
temperatur
separ
pbmc
resuspend
gibco
medium
homogen
wash
twice
rpmi
centrifug
min
room
temperatur
homogen
final
resuspend
rpmi
cellsml
briefli
mitogen
stimulu
assay
aliquot
pbmc
cellswel
ad
triplic
well
togeth
phytohaemagglutinin
sigmaaldrich
chemi
gmbh
taufkirchen
germani
incub
carri
humidifi
atmospher
mitogenicstimul
cultur
day
antigenicstimul
cultur
order
investig
immunophenotyp
featur
pbmc
cultur
flatbottom
tissu
cultur
plate
costar
cambridg
usa
well
contain
supplement
rpmi
medium
aliquot
pbmc
cellswel
ad
triplic
well
togeth
vaccin
solubl
antigen
vsa
slca
incub
carri
humidifi
atmospher
day
pbmc
remov
immunophenotyp
accord
giunchetti
et
al
total
rna
extract
spleen
sampl
carri
sv
total
rna
isol
system
kit
madison
wi
usa
follow
manufactur
instruct
strand
cdna
synthesis
total
rna
use
rtpcr
system
invitrogen
brasil
paulo
sp
brazil
oligodt
primer
accord
manufactur
instruct
total
genom
dna
extract
approxim
mg
spleen
use
genom
dna
purif
kit
madison
wi
usa
follow
manufactur
recommend
primer
use
amplifi
gapdh
gene
cytokin
design
sequenc
deposit
genbank
help
primer
express
softwar
appli
biosystem
usa
tabl
order
quantifi
parasit
burden
primer
describ
bretagn
et
al
amplifi
bp
fragment
singlecopynumb
gene
dna
polymeras
l
infantum
genbank
access
number
use
primer
amplicon
describ
tabl
cytokin
pcr
carri
final
volum
contain
mm
forward
revers
primer
green
pcr
master
mix
pe
appli
biosystem
foster
citi
ca
usa
cdna
dilut
sampl
incub
min
submit
cycl
min
collect
time
fluoresc
data
effici
pair
primer
evalu
serial
dilut
cdna
accord
protocol
develop
pe
appli
biosystem
order
evalu
gene
express
three
replic
analys
perform
amount
target
rna
normal
respect
control
housekeep
gene
gapdh
express
accord
method
result
express
log
mrna
rel
express
order
quantifi
parasit
burden
use
primer
amplifi
fragment
singlecopi
gene
dna
polymeras
l
infantum
pcr
carri
final
volum
contain
nm
forward
revers
primer
green
reaction
master
mix
appli
biosystem
usa
templat
dna
pcr
condit
follow
initi
denatur
step
min
follow
cycl
denatur
annealingextens
min
standard
curv
prepar
run
use
known
quantiti
plasmid
promega
usa
contain
insert
interest
order
verifi
integr
sampl
procedur
carri
gapdh
gene
bp
fragment
genbank
access
number
reaction
process
analyz
abi
prism
detect
system
appli
biosystem
usa
result
express
number
amastigot
per
mg
spleen
statist
analys
perform
use
prism
softwar
packag
prism
softwar
irvin
ca
usa
normal
data
demonstr
use
test
oneway
analysi
varianc
tukey
posttest
use
determin
differ
group
term
humor
immun
respons
immunophenotyp
profil
vitro
assay
time
evalu
vitro
longitudin
analys
cytokin
parasit
burden
case
differ
consid
signific
p
valu
signific
p
increas
serum
level
antileishmania
total
igg
fig
time
challeng
tbc
ie
day
experiment
challeng
day
challeng
dac
observ
lbsap
group
compar
c
sap
group
dac
well
c
sap
lb
group
tbc
dac
lb
group
show
higher
level
p
total
igg
compar
c
dac
compar
c
sap
dog
dac
fig
also
lbsap
group
elicit
higher
level
p
total
igg
dac
compar
c
sap
group
fig
moreov
lbsap
group
show
higher
level
p
tbc
dac
compar
group
c
sap
lb
compar
c
dog
dac
fig
addit
dac
observ
higher
level
p
antileishmania
lb
dog
compar
c
sap
group
fig
higher
level
p
antileishmania
observ
lbsap
group
tbc
dac
compar
group
furthermor
dac
lbsap
dog
show
increas
p
compar
c
sap
group
fig
lb
show
higher
level
p
compar
c
group
dac
fig
analysi
demonstr
ratio
lower
p
lbsap
group
compar
sap
tbc
dac
c
dac
lb
dac
group
fig
compar
analysi
cell
profil
dog
immun
lbsap
differ
vaccin
formul
show
number
circul
lymphocyt
increas
p
lb
lbsapvaccin
dog
compar
sap
group
dac
also
lb
group
show
increas
p
number
circul
lymphocyt
dac
compar
c
dog
lbsap
group
show
signific
p
augment
circul
lymphocyt
compar
lb
group
dac
fig
order
evalu
cellular
immunophenotyp
profil
enumer
frequenc
lymphocyt
major
subpopul
fig
c
result
reveal
increas
p
number
circul
lymphocyt
dog
vaccin
lb
lbsap
compar
sap
group
dac
moreov
lb
group
reveal
increas
p
lymphocyt
dac
compar
c
dog
analys
data
show
increas
p
circul
lymphocyt
lbsap
group
comparison
c
sap
group
dac
respect
also
lb
group
show
increas
p
number
circul
lymphocyt
dac
compar
c
dog
hand
lower
p
tcell
count
observ
dog
vaccin
lbsap
tbc
compar
lb
group
addit
dac
observ
increas
p
number
circul
lymphocyt
anim
vaccin
lbsap
compar
c
lb
circul
lymphocyt
show
increas
p
lb
group
dac
compar
c
dog
addit
lbsap
group
show
signific
increas
p
b
cell
dac
compar
c
sap
lb
group
fig
moreov
lb
lbsap
group
reveal
increas
p
b
cell
dac
compar
sap
dog
lb
dog
show
signific
increas
p
b
lymphocyt
compar
sap
group
dac
evalu
level
antigenpres
cell
apc
dog
vaccin
lbsap
observ
number
circul
monocyt
higher
p
dac
group
compar
c
sap
group
fig
similarli
lbsap
lb
dog
show
higher
p
absolut
number
monocyt
dac
compar
sap
c
sap
group
respect
addit
c
lb
lbsap
group
show
lower
p
absolut
number
monocyt
dac
compar
sap
group
also
observ
number
circul
monocyt
higher
p
lbsapvaccin
dog
dac
compar
sap
group
fig
explor
vitro
cell
prolifer
pbmc
use
two
differ
antigen
stimuli
vsa
l
braziliensi
order
evalu
memori
lymphoprolif
immun
respons
antigen
vaccin
compon
slca
investig
possibl
lymphoprolif
homolog
etiolog
agent
vl
l
infantum
fig
b
compar
analysi
differ
treatment
group
show
significantli
augment
p
stimul
index
dac
lbsap
dog
compar
c
dac
sap
dac
lb
dac
group
vsa
stimuli
fig
addit
lbsap
group
exhibit
higher
p
lymphoprolif
index
dac
compar
c
sap
dog
slca
stimuli
fig
order
evalu
whether
phenotyp
profil
pbmc
vaccinatedchalleng
dog
influenc
vsa
slca
stimul
well
character
cell
conduct
analysi
phenotyp
featur
pbmc
vaccinatedchalleng
dog
fig
presenc
vsa
fig
signific
increas
p
lymphocyt
index
stimul
cellnonstimul
cell
observ
lb
dog
compar
c
sap
group
dac
addit
lb
lbsap
group
show
higher
p
lymphocyt
index
compar
sap
dog
dac
contrast
lbsap
group
display
signific
decreas
p
cell
index
compar
sap
dog
dac
b
cell
index
signific
increas
p
lbsap
dog
dac
compar
sap
group
fig
evalu
slca
stimulu
fig
signific
increas
p
cell
index
observ
lb
lbsap
dog
compar
sap
group
dac
addit
lbsap
group
show
higher
p
lymphocyt
index
compar
sap
dog
dac
contrast
lbsap
group
display
signific
decreas
p
tcell
index
compar
c
sap
dog
dac
increas
p
dac
compar
dac
group
furthermor
lbsap
group
exhibit
higher
p
b
cell
index
compar
c
dac
sap
dac
group
fig
also
investig
whether
dog
vaccinatedchalleng
would
present
pbmc
differ
pattern
activ
marker
found
lbsap
group
accentu
increas
p
mhcii
express
index
compar
c
dog
fig
find
confirm
lbsap
vaccin
promot
activ
immun
respons
challeng
l
infantum
order
evalu
profil
immun
respons
vaccinatedchalleng
dog
genic
express
cytokin
assess
spleen
anim
fig
interestingli
show
higher
express
lb
lbsap
group
compar
c
group
p
hand
lbsap
dog
present
lower
express
c
sap
group
p
addit
lower
express
p
lb
lbsap
group
compar
c
sap
group
fig
also
evalu
ratio
vaccinatedchalleng
dog
fig
spleen
ratio
higher
p
lbsap
dog
c
sap
lb
group
similarli
consist
higher
p
ratio
lbsap
group
c
sap
dog
fig
main
parasitolog
featur
present
anim
summar
figur
shown
figur
lower
p
number
amastigot
observ
lbsap
group
compar
c
dog
data
associ
parasit
burden
reduct
sap
lb
lbsap
group
compar
c
anim
fig
result
indic
high
protect
potenti
lbsap
vaccin
even
long
term
challeng
dac
increas
expans
urban
vl
brazil
worldwid
show
import
emerg
reemerg
diseas
characterist
diseas
complex
relat
control
increasingli
pose
signific
epidemiolog
problem
mani
effort
made
identifi
profil
biomark
resist
suscept
cvl
increas
level
paramet
like
parasit
load
tumour
growth
express
leishmaniaspecif
cell
immunodepress
leishmaniaspecificigg
igm
iga
ige
serum
antibodi
relat
clinic
diseas
progress
contrast
increas
level
paramet
pbmc
prolifer
leishmani
antigen
stimul
tumour
necrosi
b
cell
subset
posit
leishmanin
skin
test
relat
resist
infect
dog
directli
connect
human
diseas
anim
certain
peculiar
high
suscept
infect
high
level
skin
parasit
even
without
clinic
sign
intrins
connect
human
popul
thu
develop
vaccin
cvl
may
import
tool
effect
method
indirectli
reduc
incid
human
vl
numer
anticvl
vaccin
contain
divers
antigen
adjuv
test
shown
promis
result
vaccin
deriv
whole
leishmania
antigen
still
attract
use
immunoprophylact
cvl
lowcost
product
reduc
need
handl
process
final
product
present
promis
result
control
leishmania
infect
present
work
conduct
detail
analysi
immunogen
lbsap
vaccin
dog
day
intraderm
inocul
use
l
infantum
sge
l
longipalpi
lbsap
vaccin
shown
induc
signific
immun
effect
includ
increas
ig
isotyp
higher
level
circul
lymphocyt
intens
cell
prolifer
product
vitro
stimul
higher
level
leishmaniaspecif
lymphocyt
work
observ
strong
sustain
induct
humor
immun
respons
anim
immun
lbsap
increas
level
total
igg
antileishmania
subclass
experiment
challeng
addit
observ
lbsap
group
low
ratio
valu
molano
et
al
use
recombin
vaccin
associ
bcg
obtain
similar
result
vaccinatedchalleng
dog
show
strong
serum
reactiv
increas
product
specif
igg
l
infantum
antigen
recent
fernand
et
al
demonstr
phase
ii
clinic
trial
increas
product
total
igg
dog
immun
increas
nonimmun
anim
suggest
subclass
associ
pattern
clinic
progress
cvl
hand
research
suggest
lower
level
fact
close
associ
symptomat
dog
result
agre
part
result
describ
associ
high
level
establishmentmainten
asymptomat
chronic
diseas
observ
low
ratio
valu
lbsap
group
find
suggest
lbsap
vaccin
promot
mix
profil
immun
respons
characterist
vaccin
compos
whole
leishmania
antigen
report
previou
studi
intens
humor
immun
respons
demonstr
lbsap
group
synchron
increas
count
circul
lymphocyt
dac
b
cell
tbc
dac
probabl
result
differenti
plasmocyt
consequ
higher
level
ig
secret
similar
result
observ
borjacabrera
et
al
demonstr
increas
b
lymphocyt
clinic
trial
immun
leishmun
vaccin
natur
histori
cvl
rei
et
al
report
decreas
b
cell
could
relat
increas
parasit
load
bone
marrow
sever
clinic
sign
diseas
thu
increas
b
lymphocyt
characterist
group
lbsap
may
biomark
resist
cvl
consid
cell
apc
hypothesi
howev
need
investig
addit
protect
leishmania
infect
depend
cellmedi
immun
respons
impli
effect
vaccin
must
abl
activ
cellmedi
immun
immun
anim
present
studi
observ
increas
level
cell
dac
well
cell
dac
lbsap
group
ramo
et
al
use
dna
vaccin
lack
protein
observ
alter
circul
tlymphocyt
popul
vaccin
anim
intraven
challeng
l
infantum
brazilian
endem
area
vaccin
use
show
increas
frequenc
lymphocyt
absenc
cvl
clinic
sign
month
immun
inde
sever
studi
use
natur
infect
anim
show
correl
increas
number
tcell
resist
infect
l
infantum
thu
find
suggest
lbsapvaccin
dog
present
cell
profil
consist
develop
protect
immun
l
infantum
infect
order
evalu
potenti
vaccin
increas
number
apc
measur
level
circul
monocyt
vaccin
dog
challeng
l
infantum
interestingli
observ
increas
number
cell
mainli
lbsap
group
followup
dac
studi
natur
histori
canin
diseas
shown
symptomat
anim
high
parasit
load
spleen
dramat
decreas
circul
monocyt
count
basi
result
possibl
specul
observ
increas
lbsapvaccin
dog
could
indic
resist
phenotyp
experiment
infect
l
infantum
relat
level
cell
reflect
improv
control
tissu
parasit
vaccin
dog
determin
whether
lbsap
vaccin
would
activ
pbmc
vitro
antigen
stimul
vsa
slca
measur
stimul
index
dac
cell
deriv
immun
dog
higher
cell
reactiv
follow
stimul
vsa
record
lbsap
group
measur
time
dac
wherea
stimul
slca
show
higher
cell
reactiv
dac
vaccin
group
studi
conduct
lemesr
et
al
show
increas
cell
prolifer
rate
directli
relat
increas
product
interferon
ifn
absenc
clinic
cvl
sign
vaccin
dog
challeng
l
infantum
similar
result
observ
rafati
et
al
vaccin
dog
demonstr
increas
vitro
cell
prolifer
associ
posit
intraderm
reaction
experiment
challeng
thu
find
support
hypothesi
pbmc
lbsap
group
abl
recogn
leishmania
antigen
prolifer
suggest
lbsap
vaccin
may
use
tool
cvl
vitro
cultur
pbmc
deriv
lbsap
group
stimul
vsa
slca
increas
lymphoprolifer
accompani
higher
lymphocyt
slca
dac
cell
vsa
dac
slca
dac
index
observ
group
follow
vitro
stimul
lower
tlymphocyt
index
associ
vsa
slca
dac
stimulu
et
al
show
dog
immun
whole
parasit
vaccin
show
increas
intracytoplasm
total
lymphocyt
mainli
tcell
subpopul
stimul
specif
antigen
l
infantum
taken
togeth
result
suggest
besid
tcell
popul
import
control
cvl
tcell
subset
may
also
simultan
contribut
improv
cellular
immun
respons
vaccin
dog
elimin
parasit
challeng
infect
order
evalu
activ
statu
lymphocyt
vaccinatedchalleng
dog
evalu
antigenspecif
cell
profil
ratio
express
mhcii
lymphocyt
previous
describ
observ
pbmc
lbsap
vaccin
dog
higher
sustain
mhcii
express
index
dac
cultur
stimul
slca
vitro
studi
evalu
dog
natur
infect
l
infantum
show
decreas
mhcii
express
mainli
symptomat
anim
high
parasit
burden
bone
marrow
skin
consist
result
also
demonstr
dog
asymptomat
cvl
display
enhanc
mhcii
express
circul
lymphocyt
activ
statu
togeth
lower
overal
tissu
parasit
recent
analys
measur
cytokin
supernat
elisa
mrna
express
real
time
pcr
also
use
identifi
immunolog
pattern
vaccin
dog
experiment
challeng
studi
show
highqual
biomark
immunogen
protect
leishmania
hand
increas
express
associ
increas
parasit
load
progress
diseas
studi
observ
increas
express
lb
lbsap
group
spleen
interestingli
observ
decreas
express
regulatori
cytokin
lbsap
dog
lb
lbsap
group
find
reinforc
protect
profil
lbsap
vaccin
evalu
ratio
observ
lbsap
group
show
higher
ratio
group
overal
result
suggest
dog
vaccin
lbsap
present
valuabl
biomark
immunogen
protect
canin
leishmaniasi
even
day
postchalleng
context
experiment
challeng
canin
model
report
standard
inoculum
vitro
cultur
passag
vari
concentr
parasit
use
particularli
vaccin
trial
shown
effect
infect
dog
remain
asymptomat
furthermor
work
use
sge
associ
experiment
challeng
tri
mimic
event
sand
fli
make
blood
meal
inocul
saliva
leishmania
promastigot
result
show
dog
remain
asymptomat
throughout
followup
dac
studi
thu
use
sge
suffici
replic
bite
environ
natur
histori
cvl
progress
clinic
diseas
associ
establish
larg
number
parasit
differ
tissu
howev
amount
leishmania
dna
found
bone
marrow
might
significantli
higher
measur
blood
sampl
experiment
natur
infect
studi
select
spleen
target
tissu
detect
parasit
one
major
site
parasit
nowaday
realtim
pcr
techniqu
also
use
sever
author
order
diagnos
screen
evolut
vl
quantifi
parasit
burden
present
high
sensit
accuraci
reproduc
work
appli
realtim
pcr
techniqu
quantifi
number
amastigot
per
mg
spleen
observ
lbsap
group
show
lower
parasit
furthermor
lbsap
dog
show
higher
proport
parasit
reduct
compar
lb
sap
group
thu
protect
obtain
present
studi
confirm
capac
lbsap
vaccin
limit
parasit
replic
prevent
sever
diseas
even
long
term
challeng
day
conclus
studi
demonstr
immun
lbsap
vaccin
highli
immunogen
demonstr
persist
humor
cellular
immun
respons
indic
resist
phenotyp
canin
l
infantum
infect
immun
dog
lbsap
vaccin
result
induct
high
level
total
igg
higher
level
lymphocyt
particularli
circul
b
cell
cell
import
cell
prolifer
vsaslcaspecif
lymphocyt
furthermor
lbsap
vaccin
dog
present
high
low
express
spleen
signific
reduct
parasit
load
tissu
overal
result
valid
potenti
lbsap
vaccin
protect
l
infantum
experiment
infect
strongli
support
evalu
effici
lbsap
cvl
natur
infect
condit
